Literature DB >> 20884287

Lack of correlation between three commercial platforms for the evaluation of human immunodeficiency virus type 1 (HIV-1) viral load at the clinically critical lower limit of quantification.

Celine S Yan1, Imelda Hanafi, Anthony D Kelleher, Andrew D Carr, Janaki Amin, Leon P McNally, Philip H Cunningham.   

Abstract

BACKGROUND: Concordance in plasma HIV-1 viral load quantification at the lower limit of quantification (LLOQ) is crucial for current commercial assays.
OBJECTIVE: To compare the performance of three commercial viral load assays and carry out a correlation study with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test, the Roche Cobas Amplicor HIV-1 MONITOR test, and the Abbott RealTime HIV-1 assay. STUDY
DESIGN: Assay agreement was analyzed using linear regression and Bland-Altman plots. Concordance near the clinically critical LLOQ was measured by Cohen's kappa statistics. Intra-assay precision was assessed, and assay reproducibility was measured at 50copies/mL across all three platforms.
RESULTS: While good overall correlation was observed between the assays (r≥0.93), quantitative differences exceeded 0.5log(10)copies/mL among paired results in 3.7 to 8.3% of specimens. The degree of concordance between the assays near the LLOQ was unsatisfactory, with Cohen's kappa ranging from 0.14 to 0.38. The intra-assay precision of the Abbott RealTime HIV-1 assay ranged from 0.04 to 0.15 (SD log(10)) and 1.34% to 8.37% (CV). Reproducibility at 50copies/mL for RealTime HIV-1, TaqMan, and Amplicor was 10.05, 11.04 and 5.07 (% CV), respectively.
CONCLUSION: Although good correlation was observed between the assays across their linear range, their concordance at the clinically critical LLOQ was poor. The accurate quantification of low-level viremia remains elusive, and the lack of correlation of these assays presents a challenge to the interpretation of such results and in the clinical management of HIV-infected patients. Crown
Copyright © 2010. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20884287     DOI: 10.1016/j.jcv.2010.08.016

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  9 in total

1.  Comparison of HIV-1 viral load assay performance in immunological stable patients with low or undetectable viremia.

Authors:  Gudrun Naeth; Robert Ehret; Frank Wiesmann; Patrick Braun; Heribert Knechten; Annemarie Berger
Journal:  Med Microbiol Immunol       Date:  2012-06-15       Impact factor: 3.402

2.  HIV-1 low-level viraemia assessed with 3 commercial real-time PCR assays show high variability.

Authors:  Jean Ruelle; Laurent Debaisieux; Ellen Vancutsem; Annelies De Bel; Marie-Luce Delforge; Denis Piérard; Patrick Goubau
Journal:  BMC Infect Dis       Date:  2012-04-24       Impact factor: 3.090

3.  Evaluation of the RealTime HIV-1, Xpert HIV-1, and Aptima HIV-1 Quant Dx Assays in Comparison to the NucliSens EasyQ HIV-1 v2.0 Assay for Quantification of HIV-1 Viral Load.

Authors:  Orna Mor; Yael Gozlan; Marina Wax; Fernando Mileguir; Avia Rakovsky; Bina Noy; Ella Mendelson; Itzchak Levy
Journal:  J Clin Microbiol       Date:  2015-08-19       Impact factor: 5.948

4.  Comparative performances of HIV-1 RNA load assays at low viral load levels: results of an international collaboration.

Authors:  Luke C Swenson; Bryan Cobb; Anna Maria Geretti; P Richard Harrigan; Mario Poljak; Carole Seguin-Devaux; Chris Verhofstede; Marc Wirden; Alessandra Amendola; Jurg Boni; Thomas Bourlet; Jon B Huder; Jean-Claude Karasi; Snjezana Zidovec Lepej; Maja M Lunar; Odette Mukabayire; Rob Schuurman; Janez Tomazic; Kristel Van Laethem; Linos Vandekerckhove; Annemarie M J Wensing
Journal:  J Clin Microbiol       Date:  2013-12-04       Impact factor: 5.948

5.  Ability of two commercially available assays (Abbott RealTime HIV-1 and Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Version 2.0) to quantify low HIV-1 RNA Levels (<1,000 copies/milliliter): comparison with clinical samples and NIBSC working reagent for nucleic acid testing assays.

Authors:  Alessandra Amendola; Patrizia Marsella; Maria Bloisi; Federica Forbici; Claudio Angeletti; Maria R Capobianchi
Journal:  J Clin Microbiol       Date:  2014-03-26       Impact factor: 5.948

6.  Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).

Authors:  Babafemi Taiwo; Lu Zheng; Sebastien Gallien; Roy M Matining; Daniel R Kuritzkes; Cara C Wilson; Baiba I Berzins; Edward P Acosta; Barbara Bastow; Peter S Kim; Joseph J Eron
Journal:  AIDS       Date:  2011-11-13       Impact factor: 4.177

7.  GeneXpert HIV-1 quant assay, a new tool for scale up of viral load monitoring in the success of ART programme in India.

Authors:  Smita Kulkarni; Sushama Jadhav; Priyanka Khopkar; Suvarna Sane; Rajkumar Londhe; Vaishali Chimanpure; Veronica Dhilpe; Manisha Ghate; Rajendra Yelagate; Narayan Panchal; Girish Rahane; Dilip Kadam; Nitin Gaikwad; Bharat Rewari; Raman Gangakhedkar
Journal:  BMC Infect Dis       Date:  2017-07-21       Impact factor: 3.090

8.  Short communication: HIV blips while on antiretroviral therapy can indicate consistently detectable viral levels due to assay underreporting.

Authors:  John M Murray; John J Zaunders; Kersten K Koelsch; Ven Natarajan; Yunden Badralmaa; Kristin McBride; Alexander Carrera; David A Cooper; Sean Emery; Anthony D Kelleher
Journal:  AIDS Res Hum Retroviruses       Date:  2013-08-09       Impact factor: 2.205

9.  Performance Comparison of Xpert HIV-1 Viral Load Assay and Roche Taqman and Abbott M2000 RT in Bamako, Mali.

Authors:  Bourahima Kone; Drissa Goita; Oumar Dolo; Daouda Traore; Dramane Sogoba; Amadou Somboro; Moumine Sanogo; Anou M Somboro; Nadie Coulibaly; Alou Sanogo; Zoumana Diarra; Madou Traore; Almoustapha I Maiga; Bocar Baya; Yeya Dit Sadio Sarro; Bassirou Diarra; Amadou Kone; Dramane Diallo; Djeneba Dabitao; Jane L Holl; Michael Belson; Sounkalo Dao; Robert L Murphy; Mahamadou Diakite; Souleymane Diallo; Seydou Doumbia; Mamoudou Maiga
Journal:  J AIDS Clin Res       Date:  2020-07-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.